A focused integrated evidence planning approach that identified over >£10m of savings in one year
11 December 2025
How can you enhance asset strategy and reduce cost by focusing on the evidence outcomes that truly matter to your customers?
Our client was a leading global pharmaceutical company with an ambitious 5-year pipeline of launches that required a cross-functional step-change in how they approached evidence generation. As part of a broader Baringa-led programme to redesign all their end-to-end R&D and Medical processes, they asked us to support them define a new consistent approach to Integrated Evidence Planning (IEP) and roll this out across their portfolio.
Reimagining IEP to deliver truly differentiating evidence that resonates with customers
IEP often fails because it is too internally focused, serving the needs of R&D/Medical functions, instead of delivering the compelling evidence customers want to see. We started by identifying the customer groups our client was generating evidence for – Patients, HCPs, Payers, and Policymakers/ Recommending Bodies. Then, we looked at which product outcomes mattered most to each customer, mapped the corresponding existing evidence, and pinpointed where new studies were needed to fill the gaps. Focusing attention on the ‘must have’ evidence for these customers identified significant redundant and duplicative effort between global, regional, and local teams. This shone the spotlight on > £10m of low value evidence generation activity.
Driving award-winning cross-functional collaboration
As we delivered across the portfolio, we brought together the full asset team – intentionally bridging the gap between R&D and Commercial, often for the first time. This allowed us to co-create IEPs that both served commercial goals and were achievable with the R&D resources available. Beyond ‘must have’ evidence generation, we also identified where products would require additional wraparound services, such as patient support programs, clinical decision support tools and digital applications to meet customer expectations and achieve differentiation. The scale of this cross-functional programme and its impact on internal decision-making led to an R&D award for programs that have improved the lives of patients.
Related Client Stories
Unlocking the power of patient insight to revolutionise clinical trial design
When we talk about clinical trials, discussions often centre on regulatory demands, data integrity, endpoints, and scientific outcomes. While these are undeniably critical, what frequently gets overlooked is the perspective that matters most - the patients.
Read more
Preparing a global biotech company for inspection readiness
Always being inspection ready is integral to maintaining an effective Quality Management System (QMS), ensuring regulatory compliance, safeguarding the quality and safety of pharmaceutical products, and reducing risks and issues.
Read more
Embedding cultural change at pace in a complex GxP environment
In today’s rapidly evolving regulatory and technological environment, and with increasing patient expectations, quality must transcend traditional compliance. For pharmaceutical and life sciences organisations, a bold approach to quality is not just a necessity—it’s a strategic advantage.
Read more
Optimising global R&D processes to accelerate drug approval
For large pharmaceutical companies, the ability to consistently deliver high-quality medicines to patients as quickly and efficiently as possible is a critical differentiator.
Read moreIs digital and AI delivering what your business needs?
Digital and AI can solve your toughest challenges and elevate your business performance. But success isn’t always straightforward. Where can you unlock opportunity? And what does it take to set the foundation for lasting success?